Novartis Exjade Trial Failed To Show Non-Inferiority To Desferal, FDA Says

Subset analysis conducted by Novartis may show Exjade benefit in certain patients at higher doses, according to FDA background documents for the Sept. 29 Blood Products Advisory Committee meeting.